University receives $26 million for leukemia research

The National Cancer Institute has awarded two major grants totaling $26 million to leukemia researchers and physicians at the School of Medicine. The funding has the potential to lead to novel therapies for leukemia that improve survival and reduce treatment-related side effects. Pictured are cancer cells from a patient with acute myeloid leukemia.

Drug makes leukemia more vulnerable to chemo

A new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells, according to John F. DiPersio, MD, PhD, and his colleagues at Washington University. Instead of attacking these cells directly, the drug helps drive them out of the bone marrow and into the bloodstream, where they are more vulnerable to chemotherapy.

Scientists map genetic evolution of leukemia

By mapping the evolution of cancer cells in patients with myelodysplastic syndromes who later died of leukemia, Timothy Graubert, Matthew Walter and their Washington University colleagues have found clues to suggest that targeted cancer drugs should be aimed at mutations that develop early in the disease.

Progress in fight against aggressive childhood leukemia

Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome.

Key genetic error found in family of blood cancers

Scientists have uncovered a critical genetic mutation in some patients with myelodysplastic syndromes — a group of blood cancers that can progress to a fatal form of leukemia. The research team at Washington University School of Medicine in St. Louis also found evidence that patients with the mutation are more likely to develop acute leukemia.
Older Stories